Microcoaxial phaco better than standard phaco

Article

Microcoaxial phacoemulsification induces significantly less keratometric changes and provides better visual acuity than standard phacoemulsification.

Microcoaxial phacoemulsification induces significantly less keratometric changes and provides better visual acuity than standard phacoemulsification, according to Seyed Javad Hashemian and colleagues from the Fajr Hospital & Negah Eye Hospital, Tehran, Iran.

In a controlled prospective clinical trial, 69 eyes of subjects with senile cataract (grade 3 to 4 on the Lens opacities Classification System III) underwent phacoemulsification. The subjects were randomized to undergo either microcoaxial phaco (39 eyes; Sovereign WhiteStar; AMO) or conventional phaco (30 eyes; Legacy 20000, Everest; Alcon). In each case, the incision was made into a temporarily clear cornea and a hydrophobic acrylic flexible intraocular lens (Acrysof Natural, SN60AT; Alcon) was implanted.

The researchers found that the only statistically significant difference between the two groups was the surgically induced keratometric changes at five days postoperatively. (p=0.02).

At the study's conclusion, Dr Hashemian an colleagues concluded that, although both techniques were safe and effective for cataract surgery, microcoaxial phacoemulsification induced significantly less surgical keratometric changes and yielded better visual acuity in the early postoperative days.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.